Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Rezolute reported positive interim data from its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. Of the 8 participants enrolled so far (50% of the planned 16), 6 met the primary endpoint of at least a 50% reduction in IV glucose requirements. All 6 responders also achieved complete discontinuation of intravenous glucose. One participant withdrew due to cancer progression and is counted as a non-responder; the 8th is still dosing.
Key figures
- Drug Name
- ersodetug
- Phase Of Trial
- Phase 3
- Responders
- 6
- Withdrawals
- 1
- Primary endpoint
- >=50% reduction in IV glucose requirements (GIR)
- Planned sample size
- 16
- Enrolled participants
- 8
- Complete discontinuations
- 6
- Treatment duration pivotal
- 8 weeks
- Treatment duration extension
- up to 6 months
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.